4,712 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Acquired by C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 4,712 shares of the company’s stock, valued at approximately $104,000.

A number of other large investors also recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC lifted its holdings in Teva Pharmaceutical Industries by 2,018.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,097,096 shares of the company’s stock worth $23,368,000 after purchasing an additional 1,045,305 shares in the last quarter. Gladstone Institutional Advisory LLC lifted its holdings in Teva Pharmaceutical Industries by 7.2% in the 4th quarter. Gladstone Institutional Advisory LLC now owns 154,249 shares of the company’s stock worth $3,400,000 after purchasing an additional 10,310 shares in the last quarter. Kestra Private Wealth Services LLC lifted its holdings in Teva Pharmaceutical Industries by 201.7% in the 4th quarter. Kestra Private Wealth Services LLC now owns 31,526 shares of the company’s stock worth $695,000 after purchasing an additional 21,075 shares in the last quarter. WCM Investment Management LLC lifted its holdings in Teva Pharmaceutical Industries by 125.6% in the 4th quarter. WCM Investment Management LLC now owns 135,754 shares of the company’s stock worth $3,030,000 after purchasing an additional 75,584 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB lifted its holdings in Teva Pharmaceutical Industries by 945.7% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 28,850 shares of the company’s stock worth $636,000 after purchasing an additional 26,091 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. The trade was a 30.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is owned by company insiders.

Analysts Set New Price Targets

TEVA has been the topic of a number of research reports. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Barclays reduced their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. Piper Sandler lifted their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. UBS Group reduced their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Finally, JPMorgan Chase & Co. lifted their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $23.57.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $16.24 on Friday. The company has a market cap of $18.39 billion, a P/E ratio of -11.20, a P/E/G ratio of 1.39 and a beta of 0.71. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.61 and a current ratio of 0.98. The business’s 50 day moving average price is $19.98 and its 200-day moving average price is $18.49. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.51 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.62 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.